An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC

Exclusion Criteria

• •A known history of mpox and/or smallpox
• •A known history of vaccination with 1st, 2nd or 3rd generation smallpox vaccines, or vaccine platforms that contain MVA as a vector
• •Planned MVA-based vaccination (other than study vaccination) during the trial
• •Close contact to a confirmed mpox case in the 3 weeks prior to study enrollment
• •Uncontrolled severe infection or other condition requiring hospitalization
• •Pregnancy
• •History of anaphylaxis or severe allergic reaction to any vaccine or known allergy to one of the components of the study vaccine